Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients Nov 20, 2019
Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference Nov 18, 2019
Heat Biologics Presents Additional Phase 2 Interim Data in Advanced NSCLC Patients at the SITC 34th Annual Meeting Nov 11, 2019
Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment Nov 5, 2019
Heat Biologics Announces a Poster Presentation of Updated Top Line Phase 2 Data of HS-110 plus Nivolumab after Checkpoint Inhibitor Treatment Failure in NSCLC Patients at the SITC 34th Annual Meeting Oct 24, 2019
